A recent study from the lab of the University of Kentucky’s Sanders-Brown Center on Aging Director Linda Van Eldik, Ph.D., has been published in PLOS ONE. The work centers around the idea that various anti-inflammatory drugs could be effective treatments for Alzheimer’s disease (AD). This study focused on a protein known as p38. Many labs have been working with this protein as a potential target for drug development to treat Alzheimer’s disease and other conditions with neuroinflammatory dysfunction.
Van Eldik and her team used genetic techniques to stop the production of p38 in the major immune cell type within the brain, the microglia. They tested the effects of this in an early-stage mouse model of AD to determine whether it would alter the trajectory of amyloid plaque formation, a major component of AD pathology. While the plaques themselves were not affected, the amount of microglia in proximity to these plaques was decreased, suggesting that suppression of microglial p38 may affect their interactions with aspects of AD pathology.
Some classes of anti-inflammatory drugs include p38 inhibitors, which are currently under clinical development and have shown encouraging results during recent human clinical trials. However, it is still not clear when during the disease process these p38 inhibitors should be administered and whether long-term suppression of p38 is harmful. The findings reported by the Van Eldik lab indicate that early inhibition of p38 may be able to alter interactions between brain immune cells and AD pathology, and they suggest that long-term suppression of p38 does not cause noticeable adverse effects.
As the state’s flagship, land-grant institution, the University of Kentucky exists to advance the Commonwealth. We do that by preparing the next generation of leaders placing students at the heart of everything we do and transforming the lives of Kentuckians through education, research and creative work, service and health care. We pride ourselves on being a catalyst for breakthroughs and a force for healing, a place where ingenuity unfolds. It's all made possible by our people visionaries, disruptors and pioneers who make up 200 academic programs, a $476.5 million research and development enterprise and a world-class medical center, all on one campus.
Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Numbers F32AG058456, T32AG057461 and RF1AG06485. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
